T cells from αDR3-treated donors retained function. (A-B) Lethally irradiated Balb/c recipients were intravenously injected with 2 × 10⁴luc⁺/gfp⁺-A20 mouse lymphoma cells together with TCD-BM (5 × 10⁶) and isotype/αDR3-treated T cells (1 × 10⁶) on day 0. Tumor burden (A) was monitored by BLI at indicated time points and survival (B) was monitored (*P < .05, ****P < .0001). Representative results of 2 independent experiments are shown. (C-E) Balb/c recipients were injected IV with 2 × 10⁴luc⁺/gfp⁺-BCL₁ cells on day −8 and tumor engraftment was confirmed on day −1. TCD-BM (5 × 10⁶) and isotype/αDR3-treated T cells (1 × 10⁶) were injected into lethally irradiated recipient mice with tumor. (C-D) Tumor burden was monitored by BLI at indicated time points. Results are representative of 2 independent experiments. (E) Survival data of 2 independent experiments were combined. Survival curves were compared by the log-rank test (****P < .0001; NS, not significant).